Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
February 28 2022 - 04:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates to address serious diseases, such as NASH and obesity,
today announced that management will be participating in a NASH
discussion panel at the Cowen 42nd Annual Healthcare Conference on
Tuesday, March 8 at 12:50pm ET.
A live webcast of the event will be available on the investor
relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcast will be archived
on Terns’ website for 30 days following the presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates to address serious diseases, such as
NASH and obesity. Terns’ pipeline includes three clinical stage
development programs including an FXR agonist, a VAP-1 inhibitor
and a THR-β agonist, and a preclinical GLP-1 receptor agonist
program. Terns is focused on developing combination therapies based
on clinically validated and complementary mechanisms of action to
drive meaningful clinical benefits for patients. For more
information, please visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2023 to Mar 2024